^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + MRTX1133 (KRAS G12D inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment
Published date:
10/01/2023
Excerpt:
...MRTX1133 was used in combination with cetuximab, KRASG12D-mutant colorectal cancer growth was effectively inhibited, both in vitro and in vivo....The combination of MRTX1133 and cetuximab serves as a potential and promising therapeutic approach for colorectal cancer with KRASG12D mutation.
DOI:
https://doi.org/10.21873/anticanres.16629
